FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients

The Tisch MS Research Center of New York announced the Phase II results of its FDA-approved stem cell treatment study. The research is a continuation of a Phase I trial, which was the first ever in the US to receive FDA approval to investigate the injection of stem cells into the cerebrospinal fluid of MS patients.